Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Competitors

NewAmsterdam Pharma logo
$11.37 0.00 (0.00%)
As of 09/15/2026
Compare

NAMSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Alvotech?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

In the previous week, Alvotech had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Alvotech and 1 mentions for NewAmsterdam Pharma. Alvotech's average media sentiment score of 1.87 beat NewAmsterdam Pharma's score of 0.94 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
NewAmsterdam Pharma Positive
Alvotech Very Positive

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats NewAmsterdam Pharma on 3 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Apollomics?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 1 articles in the media. Apollomics' average media sentiment score of 1.89 beat NewAmsterdam Pharma's score of 0.94 indicating that Apollomics is being referred to more favorably in the news media.

Company Overall Sentiment
NewAmsterdam Pharma Positive
Apollomics Very Positive

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Apollomics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats NewAmsterdam Pharma on 2 of the 2 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Aravive?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for NewAmsterdam Pharma and 0 mentions for Aravive. NewAmsterdam Pharma's average media sentiment score of 0.94 beat Aravive's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Aravive N/A N/A N/A

Summary

NewAmsterdam Pharma beats Aravive on 3 of the 5 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, bioAffinity Technologies and bioAffinity Technologies both had 1 articles in the media. bioAffinity Technologies' average media sentiment score of 1.89 beat NewAmsterdam Pharma's score of 0.94 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Very Positive
NewAmsterdam Pharma Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

Summary

bioAffinity Technologies and NewAmsterdam Pharma tied by winning 1 of the 2 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BioVie?

NewAmsterdam Pharma (NASDAQ:NAMSW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, BioVie had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for BioVie and 1 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.94 beat BioVie's score of 0.63 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Positive
BioVie Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
BioVie N/A N/A N/A

Summary

NewAmsterdam Pharma beats BioVie on 2 of the 3 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMSW vs. The Competition

Export
MetricNewAmsterdam PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.83B$7.20B$14.91B
Dividend YieldN/A3.65%2.57%11.71%
P/E RatioN/A14.39274.1125.36
Price / SalesN/A1,414.83697.73112.13
Price / CashN/A108.9477.7151.48
Price / BookN/A15.1410.366.22
Net IncomeN/A-$22.78M$3.49B$358.55M
7 Day Performance-2.99%-4.04%-1.73%-1.96%
1 Month Performance-25.95%-2.63%-1.44%-4.76%
1 Year Performance-11.03%37.15%18.15%5.49%

NewAmsterdam Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMSW
NewAmsterdam Pharma
N/A$11.37
flat		N/A-11.6%$0.00$7.12MN/A29
ALVOW
Alvotech
N/A$0.30
-1.5%		N/A-71.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/A-35.8%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.60
-14.7%		N/A+34.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NAMSW) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel